Indian Journal of Dermatology, Venereology & Leprology

Vol 74 | Issue 2 | Mar-Apr 2008

CONTENTS

EDITORIAL

Management of autoimmune urticaria
Arun C. Inamadar, Aparna Palit .......................................................... 89

VIEWPOINT

Cosmetic dermatology versus cosmetology: A misnomer in need of urgent correction
Shyam B. Verma, Zoe D. Draelos ........................................................... 92

REVIEW ARTICLE

Psoriasiform dermatoses
Virendra N. Sehgal, Sunil Dogra, Govind Srivastava, Ashok K. Aggarwal .......... 94

ORIGINAL ARTICLES

A study of allergen-specific IgE antibodies in Indian patients of atopic dermatitis
V. K. Somani .......................................................................................... 100

Chronic idiopathic urticaria: Comparison of clinical features with positive autologous serum skin test
George Mamatha, C. Balachandran, Prabhu Smitha .............................. 105

Autologous serum therapy in chronic urticaria: Old wine in a new bottle
A. K. Bajaj, Abir Saraswat, Amitabh Upadhyay, Rajetha Damisetty, Sandipan Dhar ................................................ 109

Use of patch testing for identifying allergen causing chronic urticaria
Ashimav Deb Sharma ............................................................................. 114

Vitiligoid lichen sclerosus: A reappraisal
Venkat Ratnam Attili, Sasi Kiran Attili .................................................. 118
BRIEF REPORTS

Activated charcoal and baking soda to reduce odor associated with extensive blistering disorders
Arun Chakravarthi, C. R. Srinivas, Anil C. Mathew .......................................................... 122

Nevus of Ota: A series of 15 cases
Shanmuga Sekar, Maria Kuruvila, Harsha S. Pai ............................................................... 125

Premature ovarian failure due to cyclophosphamide: A report of four cases in dermatology practice
Vikrant A. Saoji ...................................................................................................................... 128

CASE REPORTS

Hand, foot and mouth disease in Nagpur
Vikrant A. Saoji ..................................................................................................................... 133

Non-familial multiple keratoacanthomas in a 70 year-old long-term non-progressor HIV-seropositive man
Hemanta Kumar Kar, Sunil T. Sabhnani, R. K. Gautam, P. K. Sharma, Kalpana Solanki, Meenakshi Bhardwaj .......................................................... 136

Late onset isotretinoin resistant acne conglobata in a patient with acromegaly
Kapil Jain, V. K. Jain, Kamal Aggarwal, Anu Bansal .................................................................. 139

Familial dyskeratotic comedones
M. Sendhil Kumaran, Divya Appachu, Elizabeth Jayaseelan .................................................. 142
Nasal NK/T cell lymphoma presenting as a lethal midline granuloma
Vandana Mehta, C. Balachandran, Sudha Bhat, V. Geetha, Donald Fernandes ..................................................... 145

Childhood sclerodermatomyositis with generalized morphea
Girishkumar R. Ambade, Rachita S. Dhurat, Nitin Lade, Hemangi R. Jerajani .......................................................... 148

Subcutaneous panniculitis-like T-cell cutaneous lymphoma
Avninder Singh, Joginder Kumar, Sujala Kapur, V. Ramesh ..................................................................................... 151

LETTERS TO EDITOR

Using a submersible pump to clean large areas of the body with antiseptics
C. R. Srinivas ................................................................................................................................................................. 154

Peutz-Jeghers syndrome with prominent palmoplantar pigmentation

Stratum corneum findings as clues to histological diagnosis of pityriasis lichenoides chronica
Rajiv Joshi ..................................................................................................................................................................... 156

Author’s reply
S. Pradeep Nair ............................................................................................................................................................. 157

Omalizumab in severe chronic urticaria
K. V. Godse ..................................................................................................................................................................... 157

Hypothesis: The potential utility of topical eflornithine against cutaneous leishmaniasis
M. R. Namazi ................................................................................................................................................................ 158

Nodular melanoma in a skin graft site scar
A. Gnaneshwar Rao, Kamal K. Jhamnani, Chandana Konda ................................................................................... 159
Palatal involvement in lepromatous leprosy
A. Gnaneshwar Rao, Chandana Konda, Kamal Jhamnani

Unilateral nevoid telangiectasia with no estrogen and progesterone receptors in a pediatric patient
F. Sule Afsar, Ragip Ortac, Gulden Diniz

Eruptive lichen planus in a child with celiac disease
Dipankar De, Amrinder J. Kanwar

Xerosis and pityriasis alba-like changes associated with zonisamide
Feroze Kaliyadan, Jayasree Manoj, S. Venkitakrishnan

Treatment of actinomycetoma with combination of rifampicin and co-trimoxazole
Rajiv Joshi

Author's reply

Vitiligo, psoriasis and imiquimod: Fitting all into the same pathway
Bell Raj Eapen

Author's reply
Engin Şenel, Deniz Seçkin

Multiple dermatofibromas on face treated with carbon dioxide laser: The importance of laser parameters
Kabir Sardana, Vijay K. Garg

Author's reply

Alopecia areata progressing to totalis/universalis in non-insulin dependent diabetes mellitus (type II): Failure of dexamethasone-cyclophosphamide pulse therapy
Virendra N. Sehgal, Sambit N. Bhattacharya, Sonal Sharma, Govind Srivastava, Ashok K. Aggarwal

Subungual exostosis
Kamal Aggarwal, Sanjeev Gupta, Vijay Kumar Jain, Amit Mital, Sunita Gupta
The copies of the journal to members of the association are sent by ordinary post. The editorial board, association or publisher will not be responsible for non-receipt of copies. If any of the members wish to receive the copies by registered post or courier, kindly contact the journal's/publisher's office. If a copy returns due to incomplete, incorrect or changed address of a member on two consecutive occasions, the names of such members will be deleted from the mailing list of the journal. Providing complete, correct and up-to-date address is the responsibility of the members. Copies are sent to subscribers and members directly from the publisher's address; it is illegal to acquire copies from any other source. If a copy is received for personal use as a member of the association/society, one cannot resale or give-away the copy for commercial or library use.
Omalizumab in severe chronic urticaria

Sir,

Urticaria patients are usually treated with oral antihistamines and 50% of them respond well to this treatment. However, the other 50% do not respond to antihistamines and need a more aggressive approach. Approximately 40-50% of patients with no apparent cause for their urticaria are believed to have an associated autoimmune profile that may play a pathogenetic role. We describe here a patient who responded to omalizumab after failure to respond to cyclosporine.

A forty-five-year old female presented with severe chronic urticaria prevalent for the last ten years and which did not respond to antihistamines and steroids. About five years ago, the patient was diagnosed to have sarcoidosis and was treated with oral steroids. She had developed osteoporosis
due to repeated courses of oral steroids in the past. She also had a history of bronchial asthma, which was controlled with a bronchodilator. She was started on cyclosporine at a dose of 3 mg/kg in December 2006. Her urticaria was well controlled with cyclosporine until June 2007. Later, her urticaria worsened in spite of regular doses of cyclosporine and antihistamines in combination (hydroxyzine 25 mg three times a day and fexofenadine 180 mg daily). Hence, the dose of cyclosporine was doubled to 6 mg/kg per day (300 mg) but her urticaria was not controlled. The addition of montelukast also did not help.

Her blood investigations including complete blood counts, biochemistry and thyroid stimulating hormone (TSH) were within normal limits. Serum protein electrophoresis was normal. Autologous serum skin test could not be performed as antihistamines could be not stopped even for a single day. Serum immunoglobulin E (IgE) was 778 as against the normal level of 100. At this stage, she was started on omalizumab 300 mg every four weeks in consultation with a chest physician in addition to cyclosporine, antihistamines and montelukast. After the first injection, she showed more than 90% control of her urticaria, while after the second injection, she had total relief from her symptoms, which lasted for four weeks.

Omalizumab, a recombinant, humanized, monoclonal antibody against immunoglobulin IgE, represents a unique therapeutic approach for the treatment of allergic diseases. This agent acts as a neutralizing antibody by binding IgE at the same site on IgE as its high-affinity receptor, FεRI. Subsequently, IgE is prevented from sensitizing cells bearing high-affinity FεRI receptors. Inhibition of the biological effects of IgE targets an early phase of the allergic cascade before the generation of allergic symptoms. Omalizumab reduces serum levels of IgE and blocks the attachment of IgE to mast cells and other immune cells, thereby preventing IgE-mediated inflammatory changes. Omalizumab is approved for the treatment of moderate-to-severe persistent asthma in adults and adolescents older than 12 years of age who have a positive skin test to a perennial allergen. Dosing is based on weight and pretreatment serum IgE levels and is administered via subcutaneous injection every 2-4 weeks. The safety profile of omalizumab is favorable with injection site reaction being the most commonly reported adverse event.

There are reports of the efficacy of omalizumab in chronic urticaria and atopic dermatitis. The incidence of anaphylaxis in clinical trials for omalizumab was 0.1%. Boyce describes a successful treatment of cold urticaria with omalizumab. Anti-IgE treatment induces the depletion of free IgE from the serum and tissue, leading ultimately to reduced binding of IgE to its high-affinity surface receptor, FεRI. As occupancy of FεRI by IgE determines the levels of surface FεRI expression, this leads to a rapid depletion of both cell-bound IgE and surface FεRI expression on blood basophils.

Omalizumab may have a beneficial effect in the treatment of chronic urticaria. Further studies are needed to confirm this effect and better elucidate the mechanism for the observed improvement.

K. V. Godse
Consultant Dermatologist, Mumbai, India

Address for correspondence: Dr. Kiran Godse, Shree Skin Centre, 22, L market, Sector 8, Nerul, Navi Mumbai - 400 706 India.
E-mail: drgodse@yahoo.co.in

REFERENCES